ClinicalTrials.gg
CompletedNCT02963766AWARD-PEDSUpdated Jul 1, 2022Results posted

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

A Phase 3 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 61 sites in 11 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
29th of 54
154 · median 159
Started
2016
with 2 others
Phase 3
22 of 54
1 open now
Registered
32nd of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 3, and was the 32nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Pediatrics
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes, treated with diet and exercise, with or without metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to study screening.
  • Have >6.5% to ≤11% at screening visit. If newly diagnosed and not on medicine for diabetes, HbA1c must be between >6.5 % to ≤9%.
  • Have a (body mass index) >85 percentile for age, gender and body weight ≥50 kilograms (110 pounds).

Exclusion criteria

Exclusion Criteria:

  • Known type 1 diabetes, or positive GAD65 or IA2 antibodies, or history of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome.
  • A history of, or at risk for pancreatitis.
  • Self or family history of Multiple Endocrine Neoplasia (MEN) type 2A or B, thyroid C-cell hyperplasia or medullary thyroid cancer, or a blood calcitonin result ≥20 picograms per milliliter (pg/ml) at screening.
  • A systolic blood pressure of ≥160 millimeters of mercury (mmHg) or diastolic ≥100 mmHg.
  • Active or treated cancer.
  • A blood disorder where an accurate may not be obtainable.
  • A female of childbearing age, sexually active and not on .
  • Pregnant or plan to be pregnant during the study, or breastfeeding.
  • Taking any diabetic medication other than metformin or basal insulin and have not stopped it 3 months prior to the screening visit (6 weeks for bolus or mealtime insulin).
  • Have taken oral within the last 60 days or more than 20 days use within the past year or 1000 micrograms fluticasone propionate per day.
  • Using prescription weight loss medications in the last 30 days, or plan to use.
  • Taking psychiatric medications for depression or illness or attention deficit hyperactivity disorder (ADHD) if, the doses has changed within the last 3 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Placebo/0.75 milligram (mg) Dulaglutide

    Participants received placebo administered subcutaneously (SC) for 26 weeks during the double-blind period and open-label 0.75 mg/week dulaglutide for 26 weeks during the Open Label Extension (OLE).

    Drug: Dulaglutide · Drug: Placebo

  • Experimental
    0.75 mg Dulaglutide

    Participants received 0.75 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 0.75 mg/week for 26 weeks during the OLE.

    Drug: Dulaglutide

  • Experimental
    1.5 mg Dulaglutide

    Participants received 1.5 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 1.5 mg/week for 26 weeks during the OLE.

    Drug: Dulaglutide

Interventions

  • Administered SC

    Also known as: LY2189265

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline + insulin Use + metformin Use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in HbA1c (Individual Doses) at Week 26

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean in HbA1c was calculated using a REML based MMRM and adjusted by, baseline + insulin use + metformin use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).

    Time frame: Baseline, Week 26

  2. Change From Baseline in Fasting Blood Glucose (FBG) at Week 26

    Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group \[ less than (\<) 8%, greater than or equal to (\>=) 8%).

    Time frame: Baseline, Week 26

  3. Percentage of Participants With HbA1c ≤7.0%

    The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.

    Time frame: Week 26

  4. Change From Baseline in Body Mass Index (BMI) at Week 26

    BMI is an estimate of body fat based on body weight divided by height squared. LS mean were calculated using a MMRM analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group (\< 8%, \>= 8%).

    Time frame: Baseline, Week 26

  5. Percentage of Participants With Self-Reported Events of Hypoglycemia

    Summary and analysis of Incidence of all hypoglycemia with Plasma Glucose \<54mg/dL.

    Time frame: Week 26

  6. Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia

    Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia was summarized.

    Time frame: Week 26

  7. Number of Participants With Adjudicated Pancreatitis

    The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Week 26

  8. Change From Baseline in Pancreatic Enzymes at Week 26

    Serum Amylase (total and pancreas-derived) and lipase concentrations were measured.

    Time frame: Baseline, Week 26

  9. Number of Participants With Thyroid Treatment-Emergent Adverse Events

    Number of Participants with Thyroid Treatment-Emergent Adverse Events were summarized.

    Time frame: Week 26

  10. Change From Baseline in Serum Calcitonin at Week 26

    Change from Baseline in Serum Calcitonin was evaluated.

    Time frame: Baseline, Week 26

  11. Percentage of Participants With Allergic, Hypersensitivity Reactions

    The percentage of Participants with Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Week 26

  12. Percentage of Participants With Injection Site Reactions

    The percentage of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Week 26

  13. Number of Participants With Anti-Dulaglutide Antibodies

    Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 26 and 56. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

    Time frame: Baseline through Week 56

  14. Pharmacokinetics (PK): Maximum Concentration of Dulaglutide at Steady-state (Cmax,ss)

    PK: Maximum Concentration of Dulaglutide at steady-state (Cmax,ss) was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.

    Time frame: Week 9: pre-dose,1 to 12 hours post dose and 24 to 96 hours post dose; Week 13: predose and 1 to 12 hours post dose; Week 26: predose; Week 39: up to 2 days postdose; Week 52 and Week 56: PK sample can be taken at any time during the visit

  15. PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss]

    PK: Area Under the Concentration Time Curve over a 1-week interval of Dulaglutide at Steady-State \[AUC(0-168)ss\] was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.

    Time frame: Week 9: pre-dose,1 to 12 hours post dose and 24 to 96 hours post dose; Week 13: predose and 1 to 12 hours post dose; Week 26: predose; Week 39: up to 2 days postdose; Week 52 and Week 56: PK sample can be taken at any time during the visit

07

Results

Posted Jul 1, 2022

Participant flow

Double-Blind Period
Participant flow — Double-Blind Period
MilestonePlacebo/0.75 Milligram (mg) Dulaglutide0.75 mg Dulaglutide1.5 mg Dulaglutide
Started515152
Received at least 1 dose of study drug515152
Completed474950
Not completed422
Withdrew: Adverse event101
Withdrew: Physician decision100
Withdrew: Withdrawal by subject110
Withdrew: Withdrawal by parent or guardian001
Withdrew: Protocol violation100
Withdrew: Lost to follow-up010
Open Label Extension (OLE)
Participant flow — Open Label Extension (OLE)
MilestonePlacebo/0.75 Milligram (mg) Dulaglutide0.75 mg Dulaglutide1.5 mg Dulaglutide
Started474950
Completed454648
Not completed232
Withdrew: Physician decision122
Withdrew: Withdrawal by subject110

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline + insulin Use + metformin Use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percentage of HbA1C
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26
percentage of HbA1CPlaceboPooled Dulaglutide
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 260.5 ± 0.24-0.7 ± 0.16
Statistical analysis
  • Placebo vs Pooled Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.3 · 95% CI -1.8 to -0.7
SecondaryChange From Baseline in HbA1c (Individual Doses) at Week 26

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean in HbA1c was calculated using a REML based MMRM and adjusted by, baseline + insulin use + metformin use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c (Individual Doses) at Week 26
percentage of HbA1cPlacebo0.75 mg Dulaglutide1.5 mg Dulaglutide
Change From Baseline in HbA1c (Individual Doses) at Week 260.5 ± 0.24-0.5 ± 0.22-1.0 ± 0.22
Statistical analysis
  • Placebo vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.002 · Ls mean difference (final values): -1.0 · 95% CI -1.7 to -0.4
  • Placebo vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.5 · 95% CI -2.2 to -0.9
SecondaryChange From Baseline in Fasting Blood Glucose (FBG) at Week 26

Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group \[ less than (\<) 8%, greater than or equal to (\>=) 8%).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline in Fasting Blood Glucose (FBG) at Week 26
millimoles per liter (mmol/L)Placebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Change From Baseline in Fasting Blood Glucose (FBG) at Week 260.96 ± 0.45-0.47 ± 0.41-1.54 ± 0.41-1.03 ± 0.29
Statistical analysis
  • Placebo vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.021 · Ls mean difference (final values): -1.44 · 95% CI -2.65 to -0.22
  • Placebo vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -2.51 · 95% CI -3.72 to -1.29
  • Placebo vs Pooled Dulaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.97 · 95% CI -3.03 to -0.91
SecondaryPercentage of Participants With HbA1c ≤7.0%

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c ≤7.0%
percentage of participantsPlacebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Percentage of Participants With HbA1c ≤7.0%18.4260.0053.1956.52
Statistical analysis
  • Placebo vs 0.75 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 11.038 · 95% CI 3.491 to 34.902
  • Placebo vs 1.5 mg Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 11.666 · 95% CI 3.653 to 37.253
  • Placebo vs Pooled Dulaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 11.348 · 95% CI 4.163 to 30.932
SecondaryChange From Baseline in Body Mass Index (BMI) at Week 26

BMI is an estimate of body fat based on body weight divided by height squared. LS mean were calculated using a MMRM analysis and adjusted by baseline, strata, treatment, time, treatment\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group (\< 8%, \>= 8%).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kilograms/square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI) at Week 26
kilograms/square meter (kg/m^2)Placebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Change From Baseline in Body Mass Index (BMI) at Week 26-0.0 ± 0.21-0.2 ± 0.20-0.1 ± 0.19-0.1 ± 0.14
Statistical analysis
  • Placebo vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.689 · Ls mean difference (final values): -0.1 · 95% CI -0.7 to 0.5
  • Placebo vs 1.5 mg Dulaglutide · Mixed Models Analysis · p = 0.924 · Ls mean difference (final values): -0.0 · 95% CI -0.6 to 0.5
  • Placebo vs Pooled Dulaglutide · Mixed Models Analysis · p = 0.776 · Ls mean difference (final values): -0.1 · 95% CI -0.6 to 0.4
SecondaryPercentage of Participants With Self-Reported Events of Hypoglycemia

Summary and analysis of Incidence of all hypoglycemia with Plasma Glucose \<54mg/dL.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Self-Reported Events of Hypoglycemia
percentage of participantsPlacebo0.75 mg Dulaglutide1.5 mg Dulaglutide
Percentage of Participants With Self-Reported Events of Hypoglycemia1.963.923.85
SecondaryPercentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia

Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia was summarized.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia
percentage of participantsPlacebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia17.63.91.92.9
SecondaryNumber of Participants With Adjudicated Pancreatitis

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Week 26
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis
participantsPlacebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Number of Participants With Adjudicated Pancreatitis0000
SecondaryChange From Baseline in Pancreatic Enzymes at Week 26

Serum Amylase (total and pancreas-derived) and lipase concentrations were measured.

Time frame:
Baseline, Week 26
Reported as:
Mean · Units/Liter (U/L)
Change From Baseline in Pancreatic Enzymes at Week 26
Units/Liter (U/L)Placebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Serum Amylase0.09 ± 17.364.80 ± 9.396.50 ± 8.915.64 ± 9.15
Serum Amylase, Pancreatic0.60 ± 9.941.77 ± 4.722.90 ± 6.102.32 ± 5.45
Serum Lipase2.23 ± 31.994.37 ± 8.283.88 ± 6.634.12 ± 7.47
SecondaryNumber of Participants With Thyroid Treatment-Emergent Adverse Events

Number of Participants with Thyroid Treatment-Emergent Adverse Events were summarized.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Thyroid Treatment-Emergent Adverse Events
ParticipantsPlacebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Number of Participants With Thyroid Treatment-Emergent Adverse Events0000
SecondaryChange From Baseline in Serum Calcitonin at Week 26

Change from Baseline in Serum Calcitonin was evaluated.

Time frame:
Baseline, Week 26
Reported as:
Mean · nanograms per liter (ng/L)
Change From Baseline in Serum Calcitonin at Week 26
nanograms per liter (ng/L)Placebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Change From Baseline in Serum Calcitonin at Week 260.38 ± 1.700.28 ± 0.720.10 ± 0.500.19 ± 0.62
SecondaryPercentage of Participants With Allergic, Hypersensitivity Reactions

The percentage of Participants with Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Allergic, Hypersensitivity Reactions
percentage of participantsPlacebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Percentage of Participants With Allergic, Hypersensitivity Reactions2.03.91.92.9
SecondaryPercentage of Participants With Injection Site Reactions

The percentage of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Injection Site Reactions
percentage of participantsPlacebo0.75 mg Dulaglutide1.5 mg DulaglutidePooled Dulaglutide
Percentage of Participants With Injection Site Reactions9.89.87.78.7
SecondaryNumber of Participants With Anti-Dulaglutide Antibodies

Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 26 and 56. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

Time frame:
Baseline through Week 56
Reported as:
Number · participants
Number of Participants With Anti-Dulaglutide Antibodies
participantsPlacebo/0.75 mg Dulaglutide0.75 mg Dulaglutide1.5 mg Dulaglutide
Number of Participants With Anti-Dulaglutide Antibodies333
SecondaryPharmacokinetics (PK): Maximum Concentration of Dulaglutide at Steady-state (Cmax,ss)

PK: Maximum Concentration of Dulaglutide at steady-state (Cmax,ss) was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.

Time frame:
Week 9: pre-dose,1 to 12 hours post dose and 24 to 96 hours post dose; Week 13: predose and 1 to 12 hours post dose; Week 26: predose; Week 39: up to 2 days postdose; Week 52 and Week 56: PK sample can be taken at any time during the visit
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration of Dulaglutide at Steady-state (Cmax,ss)
nanograms per milliliter (ng/mL)0.75 mg Dulaglutide1.5 mg Dulaglutide
Pharmacokinetics (PK): Maximum Concentration of Dulaglutide at Steady-state (Cmax,ss)31 (28.4 to 33.5)62 (56.9 to 67.2)
SecondaryPK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss]

PK: Area Under the Concentration Time Curve over a 1-week interval of Dulaglutide at Steady-State \[AUC(0-168)ss\] was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.

Time frame:
Week 9: pre-dose,1 to 12 hours post dose and 24 to 96 hours post dose; Week 13: predose and 1 to 12 hours post dose; Week 26: predose; Week 39: up to 2 days postdose; Week 52 and Week 56: PK sample can be taken at any time during the visit
Reported as:
Mean · nanogram*hour per milliliter (ng*h/ mL)
PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss]
nanogram*hour per milliliter (ng*h/ mL)0.75 mg Dulaglutide1.5 mg Dulaglutide
PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss]4170 (3770 to 4510)8350 (7640 to 9070)

Adverse events

Collected over Up To 56 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: Double-Blind Period0/51 (0%)3/51 (5.9%)26/51 (51%)
0.75 mg Dulaglutide: Double-Blind Period0/51 (0%)1/51 (2%)25/51 (49%)
1.5 mg Dulaglutide: Double-Blind Period0/52 (0%)1/52 (1.9%)28/52 (53.8%)
Placebo/0.75 mg Dulaglutide: Open Label Extension (OLE)0/47 (0%)0/47 (0%)18/47 (38.3%)
0.75 mg Dulaglutide: OLE0/49 (0%)1/49 (2%)16/49 (32.7%)
1.5 mg Dulaglutide: OLE0/50 (0%)2/50 (4%)20/50 (40%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlacebo: Double-Blind Period0.75 mg Dulaglutide: Double-Blind Period1.5 mg Dulaglutide: Double-Blind PeriodPlacebo/0.75 mg Dulaglutide: Open Label Extension (OLE)0.75 mg Dulaglutide: OLE1.5 mg Dulaglutide: OLE
Pilonidal cystInfections and infestations0/510/510/520/471/490/50
PyelonephritisInfections and infestations0/510/510/520/470/491/50
Carbon monoxide poisoningInjury, poisoning and procedural complications0/510/510/520/470/491/50
Right ventricular failureCardiac disorders1/510/510/520/470/490/50
Nonalcoholic fatty liver diseaseHepatobiliary disorders0/511/510/520/470/490/50
Genital herpesInfections and infestations1/510/510/520/470/490/50
Diabetic ketoacidosisMetabolism and nutrition disorders1/510/510/520/470/490/50
Suicide attemptPsychiatric disorders1/510/510/520/470/490/50
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/510/510/520/470/490/50
Respiratory failureRespiratory, thoracic and mediastinal disorders1/510/510/520/470/490/50
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo: Double-Blind Period0.75 mg Dulaglutide: Double-Blind Period1.5 mg Dulaglutide: Double-Blind PeriodPlacebo/0.75 mg Dulaglutide: Open Label Extension (OLE)0.75 mg Dulaglutide: OLE1.5 mg Dulaglutide: OLE
DiarrhoeaGastrointestinal disorders7/518/5111/520/471/496/50
VomitingGastrointestinal disorders2/519/517/524/474/495/50
NauseaGastrointestinal disorders4/517/518/521/473/496/50
HeadacheNervous system disorders5/517/518/522/475/495/50
Upper respiratory tract infectionInfections and infestations4/512/516/523/470/491/50
Abdominal pain upperGastrointestinal disorders4/513/515/522/470/495/50
NasopharyngitisInfections and infestations3/515/512/524/471/493/50
DysmenorrhoeaReproductive system and breast disorders1/411/352/340/380/343/34
GastroenteritisInfections and infestations2/511/513/524/470/493/50
Abdominal painGastrointestinal disorders3/514/511/520/473/493/50

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo/0.75 mg Dulaglutide0.75 mg Dulaglutide1.5 mg DulaglutideTotal
Mean14.20 ± 2.0814.70 ± 2.2114.70 ± 1.8114.50 ± 2.04
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/0.75 mg Dulaglutide0.75 mg Dulaglutide1.5 mg DulaglutideTotal
Female413534110
Male10161844
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/0.75 mg Dulaglutide0.75 mg Dulaglutide1.5 mg DulaglutideTotal
Hispanic or Latino26312885
Not Hispanic or Latino25182265
Unknown or Not Reported0224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/0.75 mg Dulaglutide0.75 mg Dulaglutide1.5 mg DulaglutideTotal
American Indian or Alaska Native66416
Asian114419
Native Hawaiian or Other Pacific Islander1001
Black or African American59923
White25293084
More than one race3137
Unknown or Not Reported0224
Region of Enrollment
Region of Enrollment(Participants)Placebo/0.75 mg Dulaglutide0.75 mg Dulaglutide1.5 mg DulaglutideTotal
Brazil47516
France0224
Germany2103
India34411
Mexico14121036
Puerto Rico0112
Saudi Arabia2013
Turkey1113
United Kingdom3205
United States22212871
Percentage of Hemoglobin A1c (HbA1c) at Baseline
Percentage of Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c)Placebo/0.75 mg Dulaglutide0.75 mg Dulaglutide1.5 mg DulaglutideTotal
Mean8.14 ± 1.127.92 ± 1.278.16 ± 1.398.08 ± 1.26
08

Study locations

61 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35233, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Advanced Research Center
    Anaheim, California 92805, United States
  • Division of Endocrinology, Diabetes, and Metabolism
    Los Angeles, California 90027, United States
  • Childrens Hospital of Orange County
    Orange, California 92868, United States
  • Center of Excellence in Diabetes & Endocrinology
    Sacramento, California 95821, United States
  • Rady Childrens Hospital - San Diego
    San Diego, California 92123, United States
  • JC Cabaccan
    San Jose, California 95148, United States
  • Touro University
    Vallejo, California 94592, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Florida Center for Endocrinology & Metabolism
    Orlando, Florida 32803, United States
  • St. Luke's Regional Medical Center
    Boise, Idaho 83712, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Indiana University Health Hospital
    Indianapolis, Indiana 46202, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808-4124, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • ECU Pediatric Specialty Care
    Greenville, North Carolina 27834, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Childrens Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Seattle Children's Hospital Research Foundation
    Seattle, Washington 98105, United States
  • Multicare Health System
    Tacoma, Washington 98405, United States
  • CAMC Institute
    Charleston, West Virginia 25302, United States
  • Centro de Pesquisas em Diabetes
    Porto Alegre, Rio Grande Do Sul 90430-001, Brazil
  • Instituto da Criança com Diabetes
    Porto Alegre, Rio Grande Do Sul 91350-200, Brazil
  • Instituto Estadual de Diabetes e Endocrinologia
    Rio de Janeiro, RJ 20211-340, Brazil
  • Hospital PUC-CAMPINAS
    Campinas, Sao Paulo 13034-685, Brazil
  • CPCLIN
    São Paulo, SP 01228-200, Brazil
  • Hospital da Clinicas da Faculdade de Medicina da USP
    São Paulo, SP 05403-000, Brazil
  • Hospital das Clinicas da FMRP
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • UNIFESP - Escola Paulista de Medicina
    São Paulo, 04022-001, Brazil
  • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre
    Le Kremlin Bicetre, 94275, France
  • Hopital Robert Debre
    Paris, 75019, France
  • Praxis Dr. med. Landers
    Mayen, Rheinland-Pfalz 56727, Germany
  • Zentrum für klinische Studien
    Sankt Ingbert, Saarland 66386, Germany
  • RED-Institut GmbH
    Oldenburg in Holstein, Schleswig Holstein 23758, Germany
  • Heim Pal Gyermekkorhaz
    Budapest, 1089, Hungary
  • Sir Ganga Ram Hospital
    New Delhi, Delhi 110060, India
  • Dr Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre
    Ahmedabad, Gujarat 380007, India
  • Manipal Hospital
    Bangalore, Karmnataka 560017, India
  • M S Ramaiah Medical College Hospital
    Bangalore, Karnataka 560054, India
  • Deenanath Mangeshkar Hospital & Research Centre
    Pune, Maharashtra 411004, India
  • Post Graduate Institute of Medical Education & Research
    Chandigarh, Punjab 160012, India
  • Banaras Hindu University - BHU
    Varanasi, Uttar Pradesh 221005, India
  • Park Clinic
    Kolkata, West Bengal 700017, India
  • Apollo Gleneagles Hospitals Kolkata
    Kolkata, West Bengal 700054, India
  • Health Pharma Professional Research, S.A. de C.V.
    Mexico City, Federal District 03810, Mexico
  • Centro de Inv. Medica de Occidente, SC
    Zapopan, Jalisco 45116, Mexico
  • Centro Medico San Francisco
    Monterrey, Nuevo Leon 64710, Mexico
  • Cli-nica Hospital Cemain
    Tampico, Tamaulipas 89249, Mexico
  • Hospital Angeles Puebla
    Puebla, 72190, Mexico
  • Arke Estudios Clinicos S.A. de C.V.
    Veracruz, 91910, Mexico
  • Centro de Diabetes y Endocrinologia Pediatrica de PR
    Bayamon, 00959, Puerto Rico
  • King Saud University Hospital
    Riyadh, 11472, Saudi Arabia
  • King Salman bin Abdulaziz Hospital - Diabetic Center
    Riyadh, 12769, Saudi Arabia
  • Ankara University Medicine Hospital
    Ankara, Mamak 06100, Turkey
  • Sami Ulus Education & Research Hospital
    Ankara, 06080, Turkey
  • Duzce University Medical Faculty
    Duzce, 81620, Turkey
  • Ondokuz Mayis University Medical Faculty
    Samsun, 55139, Turkey
  • Alder Hey Children's Hospital
    Liverpool, Lancashire L14 5AB, United Kingdom
  • St James's University Hospital
    Leeds, West Yorkshire LS9 7TF, United Kingdom
09

References and documents

Publications

  • Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Perez M, Bismuth E, Dib S, Cho JI, Cox D; AWARD-PEDS Investigators. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. N Engl J Med. 2022 Aug 4;387(5):433-443. doi: 10.1056/NEJMoa2204601. Epub 2022 Jun 4. PubMed 35658022 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jun 2021, 53 months.

Results were first posted in Jul 2022, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 53 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Nov 15, 2016
StartActual
Dec 29, 2016
Primary completionActual
Jun 12, 2021
CompletionActual
Jan 12, 2022
Results first posted
Jul 1, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02963766
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Dec 29, 2016
Primary completion
Jun 12, 2021
Completion
Jan 12, 2022
Results posted
Jul 1, 2022
Last update
Jul 1, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion